^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Hormone Receptor Negative Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Perjeta (pertuzumab) (HER2 dimerization inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ecancer Medical Science
    Title:

    Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data

    Published date:
    01/06/2022
    Excerpt:
    Ninety-four women with non-metastatic breast cancer and HER2 overexpression received neoadjuvant combination chemotherapy with Trastuzumab and Pertuzumab...Seventy percent of patients achieved pCR, and in the group of hormone receptor negative patients, 89% of patients achieved pCR.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3332/ecancer.2022.1338